Before initiation of treatment D-15 to D0 | Stereotactic irradiation week FSRT Treatment of all lesions in 7-10 days maximum | End of irradiation W1 (1 week after the end of irradiation) | Follow-up visits after treatment | Follow-up after progressionf | ||||
---|---|---|---|---|---|---|---|---|
Each week up to 2 months after end of treatment W2 to W9 | 4 months after end of treatment W16 | 6 months after end of treatment W24 | Every 3 months up to disease progressionc | |||||
Stereotactic irradiation | Each brain metastasis (hemorraghic or not) will be treated at 30 Gy in 3 fractions of 10 Gy / fraction every 2 days on maximum 7 days | |||||||
Signature of informed consent | ✓ | |||||||
Clinical exam including: | ||||||||
- Disease medical history, weight, height, SC, PS) Patient pronostic (DS-GPA) | ✓ | |||||||
- Complete clinical evaluation and neurological examination | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
- Evaluation of toxicities | ✓(once a week) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
Biological assessmenta | ||||||||
- Complete Blood Count | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
- Creatinin-a | ✓ | ✓ | ✓b | ✓ | ✓ | ✓ | ||
Imagery including: | ✓ | |||||||
- Cerebral scan | ✓ | ✓ | ✓b | ✓ | ✓ | |||
- Cerebral MRI with T1 sequency Followed by Spectro-MRIe (ancillary study) | ✓ | ✓ (in case of neurological degradation due to treated lesions) | ✓ | ✓b | ✓ | ✓ | ✓ ✓ | |
Quality of life questionnaires (EORTC QLQ C30 and BN20) | ✓ | ✓ Only at 1 month | ✓ | ✓ | ✓d |